Lorundrostat is an aldosterone inhibitor associated with greater reductions in 24 hour average blood pressure than placebo impatience with uncontrolled and treatment resistant hypertension.
Lorundrostat is a highly selective aldosterone synthase inhibitor directly targeting aldosterone biosynthesis.
By inhibiting aldosterone production it spares other adrenal steroid pathways with fewer adverse effects.